Optimizing surgical performance
Over recent decades, robots have transformed cancer surgery. However, in spite of the technological advances in robotic platforms, surgeons still remain completely dependent on their sight to detect cancer intra-operatively. As a result, surgeons often leave cancer behind or remove more healthy tissue than needed. Residual disease increases the need for further drug treatment, radiotherapy, and surgery. Similarly, removing healthy, functional tissue increases post-surgical complications and escalates healthcare costs.
At Lightpoint, we are optimizing the performance of minimally-invasive and robotic cancer surgery, by developing miniaturized imaging and sensing tools to accurately detect cancer intra-operatively. The aims of the tools are to aid surgical decision making, improve patient outcomes and save costs for healthcare system.
Find out more about our miniaturized gamma probe, SENSEI®
Management team
Dr David Tuch, CEO & Founder
Simon McCoy, Finance Director
Dr David Tuch, CEO & Founder
David has more than a decade of experience in the medical imaging and pharmaceutical sectors. Previously, he was Head of Research Alliances at GE Healthcare and Head of Clinical Imaging at Novartis. Before joining industry, David served on the faculty of Harvard Medical School and Massachusetts General Hospital, Department of Radiology. He holds a PhD from MIT and Harvard Medical School, and a BA from the University of Chicago.
Claire Woodthorpe, COO
Simon McCoy, Finance Director
Dr David Tuch, CEO & Founder
Claire is responsible for the day-to-day management of Lightpoint. She has more than ten years of experience in commercial operations, including six years in the medical device industry. Before joining Lightpoint she held board level positions in technology companies specializing in research and development. Claire is a CTA-qualified accountant. She holds an LLB with Honors in Law with Accounting and Finance from the University of Liverpool.
Simon McCoy, Finance Director
Simon McCoy, Finance Director
Stewart Forbes, Head of Engineering
Simon heads up Lightpoint's finance team. He has 30 years’ experience in blue chip international organizations in the life science, healthcare, and leisure sectors. As an experienced finance leader, his diverse experience includes business strategy, business analytics, pricing, M&A activity, process improvement and streamlining, and financial management. Simon has a BA with Honors in Geography from the University of Exeter.
Stewart Forbes, Head of Engineering
Stewart Forbes, Head of Engineering
Stewart Forbes, Head of Engineering
Stewart heads Lightpoint's in-house engineering team, which includes electronics, mechanical and software engineering. The team develops Lightpoint's products from concept to regulatory-approved medical devices. Stewart is an electronics engineer with over 20 years of experience in managing engineering teams.
Tony Muller, Head of Operations
Stewart Forbes, Head of Engineering
Klaas Klooster, Head of Clinical
Tony is responsible for Lightpoint's regulatory and quality teams, as well as operational project management. He has over 30 years of experience in product development, project management and quality systems. Tony has held senior positions with blue chip companies such as GE, Unilever, the BBC.
Klaas Klooster, Head of Clinical
Stewart Forbes, Head of Engineering
Klaas Klooster, Head of Clinical
Klaas manages all of Lightpoint's multi-center clinical studies and supports clinicans running their own independent studies with our technologies. He has been managing clinical research for medical device companies for over two decades, including senior clinical positions at Stryker, Wright Medical and DePuy Synthes.
Kevin Nolan, Head of Commercial Operations
Kevin Nolan, Head of Commercial Operations
Kevin Nolan, Head of Commercial Operations
Kevin manages Lightpoint's global network of sales distributors, as well as adding commercial insight into new product development. He has over 20 years of experience in medical device business development, sales and world-wide distribution managment. Kevin has also, over many years, consulted with numerous early-stage life science companies to support product launches, determine regulatory and reimbursement strategies; and provide price analysis/positioning.
Jo O'Shea, Head of Communications
Kevin Nolan, Head of Commercial Operations
Kevin Nolan, Head of Commercial Operations
Jo is responsible for Lightpoint's external communication, as well as marketing and grant management. She has secured in excess of £8M in new non-dilutive funding for Lightpoint's R&D and clinical activities. Previous to Lightpoint she worked for over a decade in the not-for-profit sector, securing large-scale funding for charitable projects. Jo holds a BA with Honours in International History & Politics and an MPhil in Russian & East European Studies from Oxford University.
Kunal Vyas, Head of Research
Kevin Nolan, Head of Commercial Operations
Kunal Vyas, Head of Research
Kunal is responsible for Lightpoint's early-stage research before it transitions to the engineering team for formal product development. He is creating a pipeline of highly innovative technologies for intra-operative cancer detection across a wide range of major cancer indications. Kunal has almost a decade of experience in technical R&D in imaging and advanced sensors for medical devices. He holds a PhD in Experimental Physics from the University of Cambridge.
Board of directors
Dr David Tuch, Chairman & CEO
Dr David Tuch, Chairman & CEO
Dr David Tuch, Chairman & CEO
David Ford, MBA
Dr David Tuch, Chairman & CEO
Dr David Tuch, Chairman & CEO
David has more than 20 years experience in the medical device industry. Formerly the Executive Director of BSI Group, he was responsible for the worldwide Healthcare and Testing activity for the British Standards Institution. David is currently CEO at Ingenica Solutions and a Non-Executive Director at NHS TrusTECH. David has represented the United Kingdom at the World Health Organization, the FDA and the European Commission in developing policy for medical devices and medical device regulation. David was trained at St. Mary’s Hospital Medical School, London and at Brunel University, and holds an MBA from INSEAD.
Nadim Yared
Dr David Tuch, Chairman & CEO
Elizabeth Usher, MBA
Nadim is the President and Chief Executive Officer of CVRx. He has previously served as Vice President and General Manager of Medtronic Navigation, the leading global supplier of integrated image-guided surgery products. He also worked at GE Medical for 10-years, where he was Vice President of Global Marketing for the OEC Medical Systems and Vice President and General Manager of GE’s European X-ray business based in Paris. Nadim has an engineering degree from Ecole Nationale Supérieure des Télécommunications, and an MBA from INSEAD, France.
Elizabeth Usher, MBA
Elizabeth Usher, MBA
Elizabeth Usher, MBA
Elizabeth has more than 20 years of experience in the medical device industry. She is currently the Executive Director & CEO of the American Academy of Dermatology (AAD), and was previously the Chief Marketing, Sales, and Communications Officer for the College of American Pathologists (CAP). Prior to joining CAP, she held executive leadership positions at GE Healthcare and Amersham Health. She has an MBA in International Business from Thunderbird School of Global Management and a Bachelor of Science degree from Georgia Institute of Technology.
Martin Jamieson
Elizabeth Usher, MBA
Martin Jamieson
After completing his early career in the pharmaceutical industry at Wyeth and 3M, Martin worked for Smiths Medical. Over 16 years he took on increasingly senior Managing Director roles, finally as Managing Director Smiths Medical International. Latterly, Martin has served as CEO of Rayner Surgical and CEO & Chairman of Nextism Plc, a medical device company focused on improving rehabilitation for stroke patients using non-invasive brain stimulation. Martin currently works with a number of private equity houses and is a Non-Executive Director of a large NHS Foundation Trust Hospital and multiple medtech SMEs.
